News

Salvation of ocular tissues and visual acuity are dependent on early diagnosis, investigators emphasised

Highlights from the 2025 Heidelberg Engineering International SPECTRALIS Symposium—And Beyond

New financing will support the company's lead retinitis pigmentosa programme, among other projects

Consistent trends across prevalence, incidence, odds and time-to-event models suggest ocular mitochondrial disease may indicate neurodegenerative risk

Sandoz will hold exclusive or semi-exclusive marketing rights in several European and Asian countries

An ophthalmologic examination revealed bilateral anterior uveitis, though the patient had no ocular complaints at presentation

The transaction is anticipated to close in 6 to 12 months subject to customary closing conditions and regulatory approval

In a press release, the National Institute for Health and Care Excellence announced the first-ever approval for a mitochondrial disease treatment

GLP-1 therapies could impact long-term outcomes in diabetic retinopathy

Can AI compete with the well-oiled machine of the contemporary clinic?

Enhanced screenings and a unified registry could save vision and lives

The Global RDH12 Alliance unites inherited retinal disease advocacy groups including UK-based Eyes on the Future and the US-based RDH12 Fund for Sight

The IRIS is a cloud-based model that supports artificial intelligence-assisted diabetic retinopathy screening

In this insightful analysis, Dr. Joong Hun Kim presents real-world clinical outcomes with bilateral implantation of ZEISS AT ELANA 841P. Dr. Kim recommends AT ELANA® 841P as an excellent option for patients undergoing cataract surgery as its fully trifocal optical design translates into a full range of vision. He also introduces the so-called ‘ELISA’ approach for patients requiring astigmatic correction in one eye only, combining AT ELANA 841P and ZEISS AT LISA tri toric 939MP. Early objective and subjective clinical data from this novel approach reveal promising visual outcomes and high patient satisfaction

Exonate initiates a phase 2b trial for EXN407, a groundbreaking eye drop treatment for diabetic retinopathy

The companies will focus their joint effort on extended-release therapies for ocular disease

Optical coherence tomography may help identify patients at risk of cardiovascular disease before coronary angiography

According to the company, the EMA’s opinion was based on the “totality of evidence comprising a comprehensive analytical, non-clinical and clinical data package”

Rhino-orbital-cerebral mucormycosis, a life-threatening fungal infection, typically occurs in patients with diabetes

Findings from a phase 2 clinical trial support the therapeutic potential of ADX-2191 in patients with retinitis pigmentosa

The nitric oxide-donating bimatoprost therapy is intended to lower intraocular pressure in patients with glaucoma or ocular hypertension

The SYD-101 atropine formulation is licensed by Santen SA, based in Switzerland, from Sydnexis Inc, based in California

The platform, developed by University College London and Heidelberg Engineering, demonstrated accuracy and precision in early tests

Frank Kerkhoff, MD, shares his experiences with the Johnson & Johnson Tecnis Odyssey lens

The researchers shared the first cohort study established in China that examines the relationship between secondhand smoke and early onset of myopia

Researchers at the Korea Advanced Institute of Science and Technology demonstrated the next-generation strategy for sustainable synthesis

Cannabis has been shown to reduce microglial activity, expression of inflammatory cytokines and retinal neurotoxicity